Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis Ruchika Sharma23 Feb 2025 11:30 AM ISTFoster City: Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment...
Gilead Sciences Seladelpar gets positive CHMP opinion for Primary Biliary Cholangitis Ruchika Sharma15 Dec 2024 12:00 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
USFDA grants accelerated approval to Gilead Sciences Livdelzi for Primary Biliary Cholangitis Ruchika Sharma17 Aug 2024 3:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi...
Gilead Sciences to acquire CymaBay Therapeutics for USD 4.3 billion Ruchika Sharma13 Feb 2024 12:30 PM ISTFoster City: Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. have announced a definitive agreement under which Gilead will acquire CymaBay...
Seladelpar Improves Pruritus in Patients with Primary Biliary Cholangitis by reducing IL-31, shows trial Medha Baranwal9 Jan 2024 5:30 PM ISTUSA: Newly released data from a post-hoc analysis of the Phase 3 ENHANCE study has demonstrated the impact of seladelpar on serum interleukin-31...
Seladelpar significantly improves liver biochemistry and pruritus in patients with primary biliary cholangitis Dr. Shravani Dali29 Aug 2023 8:00 PM ISTSeladelpar significantly improves liver biochemistry and pruritus in patients with primary biliary cholangitis suggests a new study published in the...
Seladelpar effectively reduces alkaline phosphatase levels in patients with primary biliary cholangitis Dr. Shravani Dali17 Aug 2022 8:00 PM ISTSeladelpar showed dose-dependent efficacy in the reduction of alkaline phosphatase levels in patients with primary biliary cholangitis according to a...
